Crinetics Pharmaceuticals (CRNX) investor relations material

Executive summary

• Entered into a Merger Agreement on July 6, 2026, with Vertex Pharmaceuticals and Clark Merger Sub, making the company a wholly owned subsidiary of Vertex upon closing.

• Non-compete agreements were executed with key executives, restricting them from working with certain competitors for one year post-merger closing.

• Cash payments totaling $200,000 will be made to key executives as consideration for the non-compete agreements.

• Forward-looking statements highlight risks and uncertainties related to the merger, including regulatory approvals, integration challenges, and potential litigation.

Voting matters and shareholder proposals

• A shareholder meeting will be called to seek approval for the proposed merger transaction.

• Proxy statements and related materials will be filed and mailed to shareholders for voting on the transaction.

Board of directors and corporate governance

• Directors and executive officers of both companies may participate in the solicitation of proxies for the merger.

• Information about directors, executive officers, and their security ownership is available in recent proxy statements and SEC filings.